European Medicine Agency (EMAs) human medicines committee (CHMP) has recommended granting a conditional marketing authorization to Remdesivir for the treatment of COVID-19 in adults and adolescents from 12 years of age, with pneumonia who require supplemental oxygen, provided the recommendation is endorsed by the European Commission. Remdesivir is the first medicine against COVID-19 to be recommended for authorization, in the EU. Data on Remdesivir were assessed in an exceptionally short timeframe through a rolling review procedure, an approach used by EMA during public health emergencies to assess data as they become available.
